TODAY'S NEWS

T-DXd in Patients With Pretreated HER2-P...

A phase II clinical study investigating [fam-] tra...

---

Adding Tucatinib to Capecitabine/Trastuz...

The addition of tucatinib to capecitabine and tras...

---

Ribociclib/Letrozole vs Multiagent Chemo...

A phase II study by Gavilá et al evaluating the ef...

---

Long-Term Preventive Benefit With Anastr...

A 10-year median follow-up analysis of the IBIS-II...

---

Breast Cancer Incidence With Estrogen/Pr...

A study investigating the long-term influence of e...

More News From Today

EDITORIALS & COMMENTARY

Cytokine Release Syndrome

CAR T-cell therapy is rapidly emerging as a promising treatment for many hematologic malignancies...

---

Rare Myeloproliferative Neoplasm w/CSF3R

Cases of chronic neutrophilic leukemia (CNL) are extremely rare and easily missed...

---

Management of Carcinoid Syndrome

Diarrhea is often a presenting symptom in patients with neuroendocrine tumors...

---

APs: Collaborators in Radiation Oncology

Advanced practitioners, including physician assistants and nurse practitioners, are medical professionals with...

---

Axicabtagene Ciloleucel: CAR T-Cell Therapy

Axicabtagene ciloleucel (axi-cel) is an anti-CD19 CAR T-cell therapy that has demonstrated efficacy...

More Editorials & Commentary

PREVIOUS HIGHLIGHTS

Gemcitabine/Eribulin in Cisplatin-Inelig...

In the final analysis from a phase II California C...

---

Deintensified Chemoradiotherapy for HPV-...

In a phase II trial reported in the Journal of Cli...

---

USPSTF Recommendation on Risk Assessment...

As reported in JAMA, the U.S. Preventive Services ...

---

Incidence of HPV-Associated Head and Nec...

In a study by Mahal et al published in Cancer Epid...

---

Racial Reporting and Representation in O...

New research published by Loree et al in JAMA Onco...

More Highlights

LATEST TWEETS

Error loading Partial View script (file: ~/Views/MacroPartials/JADPRO Twitter Feed.cshtml)

More Tweets